"For some reason modern medicine has itself turned a corner and entered a darkness and is now committing crimes against humanity unequalled
in the history of our race."
 
--Dr. Mark Sircus
NATURAL HEALING 
featuring 
Alternative Cancer Treatments

INTRODUCTION: by DIANNE JACOBS THOMPSON (under construction)
1979 Around January of that year, I went home to die.   ..cont. 
I was diagnosed with stage 2 stomach cancer, chronic bronchitis, acutely infected ovarian cysts, arthritis, sciatica, low thyroid, anemia and a heart condition. Besides that I had chronic ear infections and long-standing clinical depression. The late Dr. Harold Dick, N.D., known as a "naturopathic oncology pioneer" cured me in 5 weeks. It required the diagnosis (the Carroll Food Test) of digestive enzyme deficiency food intolerances which most people have and few know about, and it also identified the primary tissue salt deficiency, along with treatment with glandular protomorphogens to restore glandular health, and Constitutional Hydrotherapy to bring about detoxification, to stimulate blood circulation and the activity of the vital organs and to jump-start the immune system. It turned out to be the basic foundation of the most successful healing system I've ever witnessed.
1986 My 5-year-old daughter was forcibly vaccinated and immediately developed a flesh-eating infection so virulent that my husband and I became infected from contact. Naturopathic medicine brought us back from the brink.
Later that year we were introduced to escharotic cancer salves and treated a dog tumor, my husband's cirrhosis of the liver, various skin lesions, moles, fungal infections, and a lump in my thigh. It eventually helped clear up the remaining symptoms from my husband's flesh-eating infection after he was forced to submit to antibiotic treatment which made a mess of it. There was much more, gallbladder problems in 1999, adrenal deficiency 2001, injury in 2002, arthritis, diabetes, and other issues between 2003-2012, including glaucoma--cured.

This is why I research and write about alternative medicine. It's a debt.

Please help support this website by purchasing hand-fired glass beads and jewelry at nitabeads1 to assist in covering the costs of books, reports, & articles needed for continuing research.


 

 

 

 


 


 

*Alternative treatments for cancer, chronic-degerative disease, infection, stress, harmful emotions and other disorders and conditions;
*Information about junk science and bad medicine, including unsafe and ineffective vaccines and undiagnosed medical conditions mimicking child abuse and Shaken Baby Syndrome;

Natural Healing Information
This site provides starting points. The rest of the journey must be yours.

"Truth wears no mask, seeks neither place nor applause, 
bows to no human shrine; she only asks a hearing"


SUBJECT: ANTIGEN TRANSFER FACTOR FOR INFECTION

A review from the Eclectic Medicine International (EMI) staff at http://www.holisticcancersolutions.com/ 

"Transfer Factor (TF) enables the recipient's immune system to deal with pathogens it couldn't successfully fight by itself.

TF is not simply a new medication; it is a whole new class of medicine, comparable in importance to antibiotics, with several significant differences. TF is a natural dietary supplement; antibiotics are not. TF works through the immune system as an "immune inducer"; antibiotics directly attack the
microorganisms. TF is definitely not a drug; antibiotics are drugs. TF is just as effective against viruses and viral type cancers as against bacteria (although presently only anti-viral formulations are available); antibiotics are useless against viruses. Finally, bacteria are becoming resistant to antibiotics. By the very nature of the procedure, this cannot happen with TF for the simple reason that the immune system of the host animal organism, through which the preparations are obtained, always reacts to the exact strain of the pathogen introduced into its system.

Although TF is just in the process of emerging as a powerful modality, the concept is certainly not new. There is more than 50 years of intensive research backing it up, with hundreds, if not thousands of papers written about it.

TF is disease specific, which means that there are specific Transfer Factors targeting single diseases, like hepatitis, HIV, Epstein-Barr virus, etc.
It is interesting to review the reasons why TF didn't become a major therapeutic tool sooner. Adoptive transfer of antigen-specific cell-mediated immunity in humans was first demonstrated in 1949 by H.S. Lawrence. His reports created little interest in the immunologic community for several reasons. In 1955, the lymphocyte was mentioned for the first time as an immunologic organ. Before this, the lymphocyte had been studied in hematologic, rather than in immunologic terms. Although Lawrence
clearly demonstrated that delayed cutaneous hypersensitivity (DH) responsiveness could also be transferred by soluble extracts of leukocytes from 20 ml of blood and termed the factor responsible for this phenomenon transfer factor (TF), at that time the significance of DH was unknown so TF received little attention. Skin testing, one of Lawrence's major research procedures, was used by allergists for whom immunologists had no respect at that time. Hence, Lawrence's observations did not excite the immunologic scientific community. At the same time, antibiotics reigned supreme, and highly respected immunologists made public statements about medical science's final victory over pathogens.

For the alternative/holistic physician, TF opens the door to a modality that deals effectively with a wide range of serious and "untreatable" conditions. The list of targeted diseases will grow monthly, as the company will release new, disease specific extracts.

What is the history of Transfer Factors (TF)?

H.S. Lawrence discovered Transfer Factors in 1949. It was shown that specific cellular immunity could be transferred from one immunized individual donor, to a non-immunized recipient. Transfer Factor is present in the leukocytes, i.e. the white cells of the blood. Its small molecular weight (less than 10,000 DA) allows its extraction by dialysis, a procedure that eliminates all molecules larger than 10,000 DA. This method of preparation totally excludes not only the presence of viral particles, but also other large molecules, which could be immunogenic for the organism and create allergic reactions. Therefore, properly manufactured Transfer Factors are totally safe and it never produces adverse side effects.

Several studies in the last 30 years have confirmed the original observations and established that dialysates from immune Iymphocytes may transfer information to naive, i.e. non- immune Iymphocytes, not only in the test tube but also when administered to laboratory animals or to patients. This information concerns only cellmediated immunity but not humoral immunity (i.e. antibody production).

Cell-mediated immunity plays a key role in the control of infectious and autoimmune diseases, as well as cancer. Thus, Transfer Factors have been utilized for the treatment of diseases caused by viruses, parasites, fungi and
mycobacterium as well as autoimmune and malignant disorders. It is worth noting that Transfer Factor is extremely potent and it can be administered in very small amounts.

The mechanisms of action of Transfer Factors at the molecular level remain largely unknown. Each batch of Transfer Factor should be stringently tested for presence, activity, and potency.

Indeed, it is now established that the leukocyte dialysates contain several immuno-active components or Iymphokines, some being antigen-specific and others antigen-non-specific. It seems that they exert their specific or
non-specific effects on the T lymphocyte (Iymphocytes responsible for cell-mediated immunity) subpopulations.

Thus, for each sub-population there is a corresponding antigen-specific and probably also a non- specific factor. This is extremely important since, by exercising a balancing effect on the different sub-populations, transfer factor
achieves immunomodulation - i.e., a regulation of the immune reactions in order for the immune system to reach a healthy equilibrium. This is one of the reasons why no adverse effects owing to overdose has ever been observed
when the dialysates were administered to patients or laboratory animals.

Furthermore, by selecting the lymphocytes from which Transfer Factors are obtained, one can enrich the final preparation with molecules stimulating the corresponding lymphocyte subpopulation of the patient, e.g. suppressor,
cytotoxic or helper.

In this way, Transfer Factors may be used to decrease over-reactivity of the immune system as in the case of allergies and autoimmune disorders, as well as to increase or re-establish impaired immunity for combating existing infections, or transfer new immunological information to prevent new infections in exposed individuals. In other words, it could also be used for prophylaxis, i.e. as a vaccine addressing the cell-mediated immunity.

See Medline articles by authors including but not limited to:

H. Fudenberg, C. Kirkpatrick, G. Paddock, G. Pizza, D. Viza, G. Wilson

IMMUNE INDUCERS
ANTIGEN SPECIFIC "TRANSFER FACTORS"

Five Decades of Research and Testing

Elevates the body's own immune system to specific antigens

Transfers distinct cell-mediated immunity to a deficient recipient

Remarkable treatment results have been achieved for viral, fungal and parasitic infections; including HIV and AIDS, Epstein~Barr virus, Herpes, Multiple Sclerosis, Alzheimer's disease, Autism, ALS (Lou Gerhig's Disease)
and Chronic Fatigue Syndrome

No known side effects: Non-toxic

A HISTORY OF HOPE - Long before many of today's immunodeficient patients were born, a significant discovery was made in 1949 by Dr. H.S. Lawrence. His discovery, now known worldwide as transfer factor (TF), spawned progressive, documented research which has had a fundamental impact on the effective treatments of patients in the 1990's.

Dr. Lawrence uncovered a vital component in the immunological maze -- the successful transfer of antigen-specific agents from a sensitized donor to an unsensitized recipient. In simpler terms, one person's immune response to a
certain disease could be precisely duplicated so that another person who had little or no immune response to the same agent could likewise fight off an infectious agent like streptococcus or Diphtheria. This "transfer factor"
was not thoroughly characterized, or for that matter understood at first, yet it was determined early on that TF was a small molecular weight ,

Other researchers, such as W. S. Jeter, came to similar conclusions about TF's capabilities in 1954. Healthy donor guinea pigs under certain circumstances, successfully transferred contact hypersensitivity to common substances, like poison ivy, to immune-deficient recipient animals.

While their contemporaries argued that prior to exposure to an antigen was likely in the recipients, Dr. Lawrence and Mr. Pappenheimer's further research brought consistent, heightened immune responses in human TF recipients. These findings were documented through extensive research done in 1960 by Rapaport et al.

Transfer factor acts as a "tailored" treatment by communicating the exact, immunological information from the donor to the recipient regarding a single, or as many as thousands of specific antigens.

In 1970, Dr. Hugh Fudenberg et al. began using TF treatment on patients suffering from Wiscott- Aldrich Syndrome. His scope later widened to include candidiasis, several viral-type cancers as well as fungal and parasitic
diseases.

Research efforts subsided somewhat during the 1970's, largely due to the high price tag coupled with a focus on mostly rare viruses. Even so, immunologists remained very interested in TF's potential, and research slowly but surely moved forward.

Over the next decade, there were continuing revelations about the nature and targeted effectiveness of TF. For example, tests were conducted in 1981 by Dr. Kahn et al. Seventeen patients with Herpes were given TF injections at intervals of one week to 3 months, with noteworthy results. Sixteen of the seventeen patients involved in the study showed definite decreases in recurrence, with eight of those treated being completely free of the disease.
T-cell function improved significantly, and it was likewise noted that TF induced interferon (production) increase. A 29 year old woman with a long history of low immune resistance contracted both generalized herpes zoster and varicella pneumonia in 1985. Her condition was described as "desperate" due to respiratory failure and an overall degrading chest condition. She responded quickly after treatment with transfer factor from a healing herpes donor.
Once again, this case points to TF's ability to effectively target specific antigens.

The Epstein-Barr virus, in combination with a cytomegalo virus (CMV) infection, was treated in a four year old child who had suffered for two years with recurring fevers, rashes, abdominal pain and other nagging symptoms. He
was then given TF by mouth. Incredibly, his symptoms disappeared, and the child even developed a specific CMV immunity.

Additional case studies revealed transfer factor's effectiveness in treating candidiasis, crypeosporosis and Burkitt's Iymphoma.
TRANSFER FACTOR TODAY - Today, in the final decade of this century, transfer factor studies are consistently showing up worldwide. Several, including those from the National Academy of Science of the United States of America, have focused on the transmission relationship between an HIV type I infected mother and her unborn child. Generally, when the mother's viral load is decreased, so is the likelihood of HIV-I being transmitted to the baby. This was observed in 1995 from a group of thirty HIV- I pregnant women.

Dr. H. Hugh Fudenberg, M.D., has greatly broadened TF research and treatment efforts. To date, he is the only one to have successfully treated subsets of Alzheimer's Disease, Autism, Chronic Fatigue Syndrome and subsets of ALS (Lou Gerhig's Disease). Similar work by others points to Myasthenia Gravis and Multiple Sclerosis as having an immunological base which can be altered or reversed through large amounts of TF.

Infected patients who are tracked up to ten years show positive, residual TF effects. A large number of peer-reviewed scientific papers testified to these facts as well as TF's consistent track record of partially or completely reversing specific viral infections. Immunological researchers continue to explore new treatment applications for TF.

Transfer Factors clearly belong to the category of primary, frontline medications against chronic viral/bacterial infections, and against autoimmune diseases that are caused by such infections. As an anti-cancer agent, TF still has to prove its efficacy; this may happen in the near future.
Lengthy studies proved that TFs taken orally are quite effective. According to experts, oral introduction is just as effective as administration by injection."

Presently, to our best knowledge, the only laboratory in the United States that produces Transfer Factors for the public is Chisolm Biological Laboratories.
In case of a specific infection that doesn't respond to any treatment, it may help to inquire about a custom made TF extract for that specific pathogen. Chisolm Labs can be reached through the distributing company, AMERIDEN.

NAME OF TREATMENT: Antigen Specific Transfer Factor (True Transfer Factors/Immmunfactors #1-6)
MANUFACTURER: Chisolm Laboratories
DISTRIBUTED BY:
AMERIDEN INTERNATIONAL P.O. Box 1870, Fallbrook, California 92088-1870
Tel: 888-405-3336 or 760-728-0747
Fax: 760-728-0608





Dianne Jacobs Thompson  Est. 2003
Also http://legaljustice4john.com
The Misdiagnosis of "Shaken Baby Syndrome" --an unproven theory without scientific support, now in disrepute and wreaking legal and medical havoc world-wide
Author publication: NEXUS MAGAZINE "Seawater--A Safe Blood Plasma Substitute?"

DISCLAIMER: The material on this site is for informational and educational purposes only. Please consult with your health care provider for treatment advice.

EMAIL: Truthquest2


Fight Spam! Click Here!